Dianthus Therapeutics (DNTH) executive compensation, 2026 proxy

Marino Garcia, President and Chief Executive Officer, was paid $10.6M in 2025, up 20% from $8.8M the year before.

Filed
April 9, 2026
Annual meeting
May 21, 2026
Pay year
2025
Named executives
3
CEO total pay
$10.6M+20% vs prior year
Prior say-on-pay support
86%of votes cast
CEO Target Bonus
55%Percentage of base salary
CFO Target Bonus
40%Percentage of base salary
R&D Head Target Bonus
45%Percentage of base salary

How Garcia was paid

$10.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Option awards89%Non-equity incentive5%All other compensation0%

Named executive officers

ExecutiveTotal
Marino GarciaPresident and Chief Executive Officer$10,614,702
Ryan SavitzExecutive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer$5,074,953
Simrat Randhawa, M.D.Executive Vice President, Head of Research and Development$5,221,537

What changed and why

  • $10.6MCEO Marino Garcia received total compensation of $10,614,702 in fiscal 2025.
  • 5%CEO base salary increased by 5% to $630,000 effective January 1, 2025.
  • Annual cash incentives were awarded based on achievement of corporate performance goals.
  • 86%The 2025 say-on-pay proposal received support from approximately 86% of votes cast.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.